Literature DB >> 19708762

Neuroendocrine tumors and tumor syndromes in childhood.

José Gaal1, Ronald R de Krijger.   

Abstract

Endocrine and neuroendocrine cells form a large and diverse array of cell types. They are present in the form of specialized organs, such as the pituitary, parathyroid, thyroid, and adrenal gland, or in the form of the diffuse neuroendocrine system in the respiratory and digestive tracts. Neuroendocrine tumors are a heterogeneous group of neoplasms, yet they present certain unifying features. These include frequent hormonal overproduction that leads to specific symptoms and a typical immunohistochemical staining profile with chromogranin A and synaptophysin reactivity. Over the past decades, many neuroendocrine tumors have been described in the context of heritable tumor syndromes, and there exist several syndromes that are almost entirely composed of neuroendocrine tumors. Tumors occurring as part of these hereditary syndromes are characterized by specific genetic abnormalities that have helped our understanding of tumorigenesis, and they frequently appear at a young age. It is therefore important for the pediatric pathologist to be aware of specific histologic characteristics of neuroendocrine tumors in childhood and of their association with specific tumor syndromes. This may alert other clinicians to the possibility of multiple tumors in the patient or his family members. This review focuses on hereditary syndromes with neuroendocrine tumors, including multiple endocrine neoplasia types 1 and 2, Von Hippel-Lindau disease, neurofibromatosis type 1, Carney complex, pheochromocytoma-paraganglioma syndrome, and familial nonmedullary thyroid carcinoma. In addition, several individual neuroendocrine tumors are described, such as medullary thyroid carcinoma, gastroenteropancreatic tumors, pheochromocytoma, and paraganglioma, emphasizing specific histopathologic characteristics.

Entities:  

Mesh:

Year:  2009        PMID: 19708762     DOI: 10.2350/09-04-0635-CP.1

Source DB:  PubMed          Journal:  Pediatr Dev Pathol        ISSN: 1093-5266


  7 in total

1.  Novel insights into the polycythemia-paraganglioma-somatostatinoma syndrome.

Authors:  Roland Därr; Joan Nambuba; Jaydira Del Rivero; Ingo Janssen; Maria Merino; Milena Todorovic; Bela Balint; Ivana Jochmanova; Josef T Prchal; Ronald M Lechan; Arthur S Tischler; Vera Popovic; Dragana Miljic; Karen T Adams; F Ryan Prall; Alexander Ling; Meredith R Golomb; Michael Ferguson; Naris Nilubol; Clara C Chen; Emily Chew; David Taïeb; Constantine A Stratakis; Tito Fojo; Chunzhang Yang; Electron Kebebew; Zhengping Zhuang; Karel Pacak
Journal:  Endocr Relat Cancer       Date:  2016-09-27       Impact factor: 5.678

2.  Much more than anxiety...

Authors:  Joana Teixeira; Marta Almeida; Mariana Afonso; Armando Pinto
Journal:  BMJ Case Rep       Date:  2015-08-05

3.  WHO Grade 2 Neuroendocrine Tumor in a 15-Year-Old Male: A Case Report and Literature Review.

Authors:  Eric Johannesen; Van Nguyen
Journal:  Case Rep Pathol       Date:  2014-11-30

Review 4.  Effect of Neuroendocrine Neoplasm Treatment on Human Reproductive Health and Sexual Function.

Authors:  Virginia Zamponi; Anna La Salvia; Maria Grazia Tarsitano; Nevena Mikovic; Maria Rinzivillo; Francesco Panzuto; Elisa Giannetta; Antongiulio Faggiano; Rossella Mazzilli
Journal:  J Clin Med       Date:  2022-07-08       Impact factor: 4.964

5.  A review of the use of somatostatin analogs in oncology.

Authors:  Ozge Keskin; Suayib Yalcin
Journal:  Onco Targets Ther       Date:  2013-04-26       Impact factor: 4.147

6.  (68)Ga-DOTATATE positron emission tomography/computed tomography scan in the detection of bone metastases in pediatric neuroendocrine tumors.

Authors:  Reema Goel; Jaya Shukla; Deepak Bansal; Kushaljit Sodhi; Anish Bhattacharya; Ram Kumar Marwaha; Bhagwant Rai Mittal
Journal:  Indian J Nucl Med       Date:  2014-01

7.  Long-term follow-up and clinical course of a rare case of von Hippel-Lindau disease: A case report and review of the literature.

Authors:  Y U Zou; Jingjing Xu; Minming Zhang
Journal:  Oncol Lett       Date:  2016-03-29       Impact factor: 2.967

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.